Pharmaceutical

VTE risk elevated in Swedish patients hospitalised for Covid-19

In this 2023 study, Sjoland and other researchers found an elevated excess risk of VTE after 180 days in patients hospitalised for Covid-19.

Sep 5, 2023 - 20:00
VTE risk elevated in Swedish patients hospitalised for Covid-19
In this 2023 study, Sjoland and other researchers found an elevated excess risk of VTE after 180 days in patients hospitalised for Covid-19.
Read the original article

Tags:

Previous Article

New 2023 guidelines for the management of cardiomyopathies

Next Article

invIOs’s cell therapy secures Austrian Government grant for Phase Ib trial

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Nuvectis Pharma receives IND approval from FDA for NXP900

Nuvectis Pharma receives IND approval from FDA for NXP900

May 16, 2023

Covid-19, a disease with tricks up its sleeve, hasn’t fallen into a seasonal pattern — yet

Covid-19, a disease with tricks up its sleeve, hasn’t f...

Aug 23, 2023

Syros Pharmaceuticals gets grant for CDK7 inhibitors for treating cancer and other diseases

Syros Pharmaceuticals gets grant for CDK7 inhibitors fo...

Jun 12, 2024